Lead Sponsor

AstraZeneca

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histological or cytological confirmation of an advanced solid malignant tumour (or lymphoma Part A only)
•Cancer which is refractory to standard therapies or for which no standard therapy exists, patients with measurable or non-measurable disease (according to RECIST criteria) can be recruited to Part A
•Evidence of post-menopausal status or negative urine/serum pregnancy test for pre-menopausal female patients

•Patients with severe laboratory abnormalities for haematology, liver or renal function. Also treatment with any haemopoietic growth factors are not allowed within two weeks from first dose of study drug.
•Patients with abnormal fasting glucose, have type I or II Diabetes or have uncontrolled blood fats and cholesterol
•Patients with a history of neurological disease, peripheral or central neuropathy, brain metastases or family history of myopathy are excluded
•Patients with severe cardiac condition of ischemia, impaired ventricular function and arrhythmias, evidence of severe or uncontrolled systemic or current unstable or uncompensated respiratory or cardiac conditions

Related studies

NCT07060989 · Advanced Solid Tumors

NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation

NCT05533697 · Advanced Solid Tumors

NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

A Study of Tor Kinase Inhibitor in Advanced Tumors